Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen *
Pharmacy Only: Prescription
Show product notice

  • Company:

    AstraZeneca Pharmaceuticals (Ireland) DAC
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

  • What is a Patient Information Leaflet and why is it useful?

    A Patient Information Leaflet (PIL) is the leaflet containing information on taking or using a medicine for patients, included with medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean the version on may differ from the version found with your medicine.

  • 20210111 Package Leaflet IE MT Bydureon DCP PRAC CV 21 0002

    Last updated: 15/01/21

Product Notice

Discontinued Strength Notice

Bydureon 2 mg Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-Filled Pen has been discontinued. It is expected that stock will be depleted by September 2022.